Cargando…

Dissecting the Molecular Features of Systemic Light Chain (AL) Amyloidosis: Contributions from Proteomics

Amyloidoses are characterized by aggregation of proteins into highly ordered amyloid fibrils, which deposit in the extracellular space of tissues, leading to organ dysfunction. In AL (amyloid light chain) amyloidosis, the most common form in Western countries, the amyloidogenic precursor is a misfol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rognoni, Paola, Mazzini, Giulia, Caminito, Serena, Palladini, Giovanni, Lavatelli, Francesca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471912/ https://www.ncbi.nlm.nih.gov/pubmed/34577839 http://dx.doi.org/10.3390/medicina57090916

Ejemplares similares

Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis: insights into the timing of proteolysis
por: Lavatelli, Francesca, et al.
Publicado: (2021)

Protease‐sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation
por: Mazzini, Giulia, et al.
Publicado: (2021)

Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient
por: Swuec, Paolo, et al.
Publicado: (2019)

In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study
por: Ami, Diletta, et al.
Publicado: (2016)

Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis
por: Palladini, Giovanni, et al.
Publicado: (2021)

Light Chain Amyloidosis
por: Milani, Paolo, et al.
Publicado: (2018)

Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells
por: Imperlini, Esther, et al.
Publicado: (2017)

DUAL expectations in light chain amyloidosis
por: Schönland, Stefan, et al.
Publicado: (2020)

A Strategy for Synthesis of Pathogenic Human Immunoglobulin Free Light Chains in E. coli
por: Rognoni, Paola, et al.
Publicado: (2013)

Novel Therapies in Light Chain Amyloidosis
por: Milani, Paolo, et al.
Publicado: (2017)

Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensity
por: Oberti, Luca, et al.
Publicado: (2017)

PB2151: CLINICAL FEATURES AND OUTCOMES OF DIFFUSE PULMONARY LIGHT CHAIN AMYLOIDOSIS: A RARE PRESENTATION OF SYSTEMIC AL AMYLOIDOSIS
por: Chakraborty, Rajshekhar, et al.
Publicado: (2023)

AA-amyloidosis in cats (Felis catus) housed in shelters
por: Ferri, Filippo, et al.
Publicado: (2023)

Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy
por: Milani, Paolo, et al.
Publicado: (2020)

AL AMYLOIDOSIS: MECHANISMS OF DISEASE AND BIOMARKERS
por: Palladini, Giovanni, et al.
Publicado: (2022)

Sars-Cov-2 Infection and Systemic Light Chain Amyloidosis: The International Society of Amyloidosis' Survey
por: Milani, Paolo, et al.
Publicado: (2020)

Systemic amyloidoses and proteomics: The state of the art
por: Lavatelli, Francesca, et al.
Publicado: (2016)

Light Chain (AL) Amyloidosis: The Journey to Diagnosis
por: McCausland, Kristen L., et al.
Publicado: (2017)

Light chain (AL) amyloidosis: update on diagnosis and management
por: Rosenzweig, Michael, et al.
Publicado: (2011)

Racial disparities in patients diagnosed with light chain (AL) amyloidosis
por: D’Souza, Anita, et al.
Publicado: (2021)

Light Chain (AL) Cardiac Amyloidosis: A Diagnostic Dilemma
por: Abdelazeem, Basel, et al.
Publicado: (2021)

Differences in Immunoglobulin Light Chain Species Found in Urinary Exosomes in Light Chain Amyloidosis (AL)
por: Ramirez-Alvarado, Marina, et al.
Publicado: (2012)

The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018
por: Palladini, Giovanni, et al.
Publicado: (2023)

Cryo-EM structure of ex vivo fibrils associated with extreme AA amyloidosis prevalence in a cat shelter
por: Schulte, Tim, et al.
Publicado: (2022)

Light Chain Stabilization: A Therapeutic Approach to Ameliorate AL Amyloidosis
por: Morgan, Gareth J., et al.
Publicado: (2021)

Feature tracking cardiac magnetic resonance in systemic light chain amyloidosis
por: Kammerer, Rebekka, et al.
Publicado: (2013)

The clinical features and outcomes of systemic light chain amyloidosis with hepatic involvement
por: Zhao, Liang, et al.
Publicado: (2022)

Exploring the sequence features determining amyloidosis in human antibody light chains
por: Rawat, Puneet, et al.
Publicado: (2021)

Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis
por: Wechalekar, A D, et al.
Publicado: (2017)

PB1989: LIGHT CHAIN AMYLOIDOSIS (AL): THE EXPERIENCE OF A TUNISIAN CENTER
por: Kallel, F., et al.
Publicado: (2022)

Supportive Care and Symptom Management for Patients With Immunoglobulin Light Chain (AL) Amyloidosis
por: Jensen, Christopher E., et al.
Publicado: (2022)

Mutations in Specific Structural Regions of Immunoglobulin Light Chains Are Associated with Free Light Chain Levels in Patients with AL Amyloidosis
por: Poshusta, Tanya L., et al.
Publicado: (2009)

Dissection of the amyloid formation pathway in AL amyloidosis
por: Kazman, Pamina, et al.
Publicado: (2021)

Primary Light-chain Amyloidosis Featuring Worm-like Small Bowel Polyposis
por: Nishimura, Naoyuki, et al.
Publicado: (2017)

Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p
por: Wong, Sandy W., et al.
Publicado: (2018)

Bone Marrow Microenvironment in Light-Chain Amyloidosis: In Vitro Expansion and Characterization of Mesenchymal Stromal Cells
por: Valsecchi, Chiara, et al.
Publicado: (2021)

Splenic rupture secondary to amyloid light-chain (AL) amyloidosis associated with multiple myeloma
por: Buzalewski, Jarrod, et al.
Publicado: (2019)

Lingual liability: macroglossia and dyspnoea as the harbinger of systemic AL (light-chain) cardiac amyloidosis
por: Williams, Michael Uncle, et al.
Publicado: (2018)

Understanding Mesangial Pathobiology in AL-Amyloidosis and Monoclonal Ig Light Chain Deposition Disease
por: Herrera, Guillermo A., et al.
Publicado: (2020)

Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives
por: Sarosiek, Shayna, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_h4gbckh9ton72pfd9tb8a8f53e